Report cover image

Global Beyond the Pill Market Growth (Status and Outlook) 2023-2029

Publisher LP Information, Inc.
Published May 30, 2023
Length 102 Pages
SKU # LPI17973594

Description

Global Beyond the Pill Market Growth (Status and Outlook) 2023-2029


The global Beyond the Pill market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The beyond the pill market has seen significant growth in recent years, driven by factors such as the increasing importance of patient-centered care, the rise of digital health technologies, and the growing demand for value-based healthcare. Key players in the beyond the pill market include major pharmaceutical companies such as Pfizer, Roche, Novartis, and Sanofi, as well as a number of smaller startups and technology companies.

The beyond the pill market is expected to continue to grow as more pharmaceutical companies recognize the importance of providing holistic healthcare solutions and as patients continue to demand more personalized and integrated care.

Beyond the pill refers to a shift in the pharmaceutical industry towards providing holistic healthcare services and products that go beyond traditional drug-based treatments. The term "beyond the pill" emphasizes the need for pharmaceutical companies to provide additional support and services to patients beyond simply prescribing medications.Beyond the pill offerings can include a wide range of products and services, such as patient education programs, digital health technologies, medical devices, and patient monitoring services. The goal of these offerings is to improve patient outcomes and satisfaction while also providing additional revenue streams for pharmaceutical companies.

LPI (LP Information)' newest research report, the “Beyond the Pill Industry Forecast” looks at past sales and reviews total world Beyond the Pill sales in 2022, providing a comprehensive analysis by region and market sector of projected Beyond the Pill sales for 2023 through 2029. With Beyond the Pill sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Beyond the Pill industry.

This Insight Report provides a comprehensive analysis of the global Beyond the Pill landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Beyond the Pill portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Beyond the Pill market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Beyond the Pill and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Beyond the Pill.

This report presents a comprehensive overview, market shares, and growth opportunities of Beyond the Pill market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Services
Monitoring
Assistance

Segmentation by application
Diabetes
Oncology
Cardiovascular Diseases
Asthma
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
Sanofi S.A
Novo Nordisk A/S
Eli Lilly and Company
F. Hoffmann-La Roche AG (Flatiron Health)
Otsuka Pharmaceuticals Co., Ltd
Amgen, Inc.
AstraZeneca Plc
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

102 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Beyond the Pill Market Size by Player
4 Beyond the Pill by Regions
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Beyond the Pill Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us